Search Results
2023 WMIF | The Disruptors: The Next Wave of Promising Psychiatry and Neurology Drugs
The Promising Pathway Act rethinks access to life-saving drugs
Neuropsychopharmacology Reviews: Neurotherapeutics
Treating Schizophrenia with Muscarinic Antipsychotics | Steve Paul
Amylyx Pharmaceuticals' AMX0035 for ALS receives negative CHMP opinion
Amylyx receives the 2021 Essey Commitment to Cures Award
Precision Medicine and Drug Development - Dr Hardiman
2022 Symposium Vigil Neuroscience, Inc. Update presented by Dr. Andreas Meier
UCL QS Institute of Neurology Inaugural Lectures: Professor Sonia Gandhi & Professor Ed Wild
Doctor discusses newly-approved ALS drug made by Massachusetts company
Amylyx Pharmaceuticals AMLX Q2 2023 Earnings Call & Presentation
